**REMARKS** 

1. Claims 33 and 34 were rejected under 35 USC 102(b) as anticipated by Stegmann (US

5486165).

2. Claim 33 has been amended to clarify that the microcannula based microsurgical device

is inserted into the segment of Schlemm's Canal that has been previously expanded using

the flexible microcannula. By contrast, in the Stegmann reference, the second tube 20' is

configured as a mirror image of the first tube 20 so that it can be inserted into a different

segment of Schlemm's Canal. (Column 4, lines 42-49.) The configuration of the second

tube 20' makes it unsuitable for insertion into the same segment of Schlemm's Canal that

was previously occupied by the first tube 20. (See FIG. 8.)

Claim 34 further distinguishes Stegmann by the novel step of "removal of tissues from the

inner wall of Schlemm's Canal." Stegmann does not disclose the removal of tissues from

within Schlemm's Canal. The only direct manipulation of tissue that occurs in Stegmann is

the initial incision that is made in order to gain access to Schlemm's Canal. (See FIGS. 3

and 4.) A flap 13' is made, but no tissue is removed. Furthermore, the incision is made

from the scleral surface, therefore the flap 13' is made on the *outer wall* of Schlemm's

Canal, rather than the *inner wall*.

Claims 33 and 34 are therefore submitted to be patentable over Stegmann (US 5486165)

under 35 USC 102(b).

3. Examiner stated that claim 35 was rejected under 35 USC 102(b) as anticipated by

Stegmann (US 5486165) in view of Grieshaber (US 2002/0013546).

4. This is an improper rejection under 35 USC 102(b) because references cannot be

combined under this statute. Examiner is requested to withdraw the rejection or to clarify

the rejection in a subsequent *non-final* Office Action.

However, in order to hasten prosecution and allowance of the claims, Applicant points out

that claim 35 distinguishes both Stegmann and Grieshaber by the novel features recited in

base claim 33, namely that the microcannula based microsurgical device is inserted into the

Response to Office Action Mailed August 4, 2010 Serial Number 10/555,065

Docket No. 336-002US

Page 8 of 12

segment of Schlemm's Canal that has been previously expanded using the flexible

microcannula. Furthermore, since neither reference discloses this novel feature, no possible

combination of the two references could result in the claimed invention.

5. Claims 30-31 were rejected under 35 USC 103(a) as unpatentable over Stegmann (US

5486165) in view of Rainin (US 5599330) or John (US 2004/0122352).

6. Applicant respectfully traverses the rejection of claims 30-31. Examiner erroneously

states that Stegmann utilizes suction in the disclosed method; however there is no mention

of suction anywhere in the reference. The section cited by Examiner (column 3, lines 23-

29) has nothing to do with the application of suction. Stegmann is actually describing the

natural flow of aqueous humour within the eye, as shown in FIG. 2. Applicant notes that

there are not even any devices present within the eye shown in FIG. 2 that could apply the

fictitious suction alleged by Examiner. Applicant contends that Examiner would never

have made this misinterpretation of the reference without the hindsight provided by

applicant's own patent application.

There is no suggestion or motivation in the Stegmann reference to apply suction through

any part of the disclosed apparatus. Furthermore, applicant points out that Rainin and John

both disclose devices that apply suction to the *exterior* of a patient's eye. There is no

suggestion or motivation in these secondary references to apply suction through a device

that is inserted into Schlemm's Canal within the eye.

Examiner's rejection was based on an erroneous interpretation of the primary reference.

Without this misinterpretation, there is no suggestion or motivation to combine the

references as proposed by Examiner. Examiner is respectfully requested to withdraw the

rejection of claims 30-31.

7. Claim 32 was rejected under 35 USC 103(a) as unpatentable over Stegmann (US

5486165) in view of Rainin (US 5599330) or John (US 2004/0122352) and further in view

of Bylsma (US 2006/0221078).

8. As with claims 30-31 above, Examiner's rejection was based on an erroneous

interpretation of Stegmann, the primary reference. Without this misinterpretation, there is

Page 9 of 12

Response to Office Action Mailed August 4, 2010 Serial Number 10/555,065

Docket No. 336-002US

no suggestion or motivation to combine Rainin or John with Stegmann, as proposed by

Examiner. For this reason, Examiner is respectfully requested to withdraw the rejection of

claim 32.

Furthermore, as pointed out in reference to claim 34 above, Stegmann does not disclose the

removal of material from within Schlemm's canal as erroneously stated by Examiner.

There is no suggestion or motivation to combine from Bylsma because it is directed to an

entirely different approach to treating glaucoma. Rather than repairing Schlemm's canal to

establish normal drainage, Bylsma seeks to bypass the normal drainage pathway by

installing a glaucoma drain 100 to drain aqueous humour externally. Without Examiner's

misinterpretation of the primary reference, there is no suggestion or motivation to combine

the tissue cutting device of Bylsma with Stegmann. For this additional reason, Examiner is

also requested to withdraw the rejection of claim 32.

9. New claims 36-64 are submitted to be patentable over the prior art of record for the

reasons stated above and by virtue of the additional novel and unobvious features recited

therein. No new matter has been added.

Response to Office Action Mailed August 4, 2010 Serial Number 10/555,065

Docket No. 336-002US

Page 10 of 12

## **CONCLUSION**

For all the reasons above, Applicant submits that the claims all define novel subject matter that is nonobvious. Therefore, allowance of these claims is submitted to be proper and is respectfully requested.

Applicant invites the Examiner to contact Applicant's representative as listed below for a telephonic interview if so doing would expedite the prosecution of the application.

Very respectfully submitted,

/James J. Leary/

James J. Leary GSS Law Group 3900 Newpark Mall Rd Third Floor, Suite 317 Newark, CA 94560 Reg. No. 35,237 Phone (510) 742-7417 Fax (510) 742-7419 Direct phone (636) 600-0255